Supplementary Figure 7 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
Arthur B. McKie, Hani Gabra(Royal Children's Hospital), Naomi E. Chayen(Imperial College London), Sebastian Vaughan(Ovarian Cancer Action), Dmitry Shaposhnikov, Elisa Zanini, Joshua L. C. Wong, Roshan Agarwal(Imperial College Healthcare NHS Trust), Mona El‐Bahrawy(Al-Azhar University), Eric W.‐F. Lam(Ottawa Hospital), Qiang Wang(Huazhong Agricultural University), Camila de Sousa, Imoh S. Okon, Mark I. Greene(University of Pennsylvania), Hatice Güngör(Ovarian Cancer Action), Louay Louis, Szymon Janczar(Hammersmith Hospital)
Cited by 0
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
|The Lancet|2019|287
FOXO transcription factor family in cancer and metastasis
|Cancer and Metastasis Reviews|2020|287